Spero Therapeutics, Inc. (SPRO)
NASDAQ: SPRO · Real-Time Price · USD
2.680
+0.040 (1.52%)
At close: Apr 16, 2026, 4:00 PM EDT
2.660
-0.020 (-0.75%)
After-hours: Apr 16, 2026, 7:44 PM EDT
Spero Therapeutics Employees
Spero Therapeutics had 25 employees as of December 31, 2025. The number of employees decreased by 7 or -21.88% compared to the previous year.
Employees
25
Change (1Y)
-7
Growth (1Y)
-21.88%
Revenue / Employee
$2,672,080
Profits / Employee
$342,880
Market Cap
155.15M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 25 | -7 | -21.88% |
| Dec 31, 2024 | 32 | -14 | -30.43% |
| Dec 31, 2023 | 46 | 11 | 31.43% |
| Dec 31, 2022 | 35 | -111 | -76.03% |
| Dec 31, 2021 | 146 | 57 | 64.04% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Humacyte | 184 |
| Innate Pharma | 174 |
| Fate Therapeutics | 161 |
| Molecular Partners AG | 134 |
| Tenaya Therapeutics | 70 |
| Connect Biopharma Holdings | 64 |
| Black Diamond Therapeutics | 21 |
| Galectin Therapeutics | 9 |
SPRO News
- 21 days ago - Spero Therapeutics Announces Fourth Quarter and Full Year 2025 Operating Results and Provides a Business Update - GlobeNewsWire
- 4 weeks ago - Spero Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on March 26, 2026 - GlobeNewsWire
- 4 months ago - Spero Announces NDA Resubmission of Tebipenem HBr by GSK to the FDA for the Treatment of Complicated Urinary Tract Infections, Including Pyelonephritis - GlobeNewsWire
- 4 months ago - Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 5 months ago - Spero Therapeutics Announces Third Quarter 2025 Operating Results and Provides a Business Update - GlobeNewsWire
- 5 months ago - Spero Therapeutics to Report Third Quarter 2025 Financial Results and Provide Business Update on November 13, 2025 - GlobeNewsWire
- 6 months ago - PIVOT-PO Phase 3 Data Show Tebipenem HBr's Potential as the First Oral Carbapenem Antibiotic for Patients with Complicated Urinary Tract Infections (cUTIs) - GlobeNewsWire
- 6 months ago - Spero Therapeutics Announces Presentations on Tebipenem Hbr at IDWeek - GlobeNewsWire